Global Non Small-Cell Lung Cancer Market By Type, By Treatment Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

List of Tables

The global non-small cell lung cancer treatment market was valued at $15,335.0 million in 2021, and is projected to reach $36,934.19 million by 2031, registering a CAGR of 9.3% from 2022 to 2031.

Non-small cell lung cancer (NSCLC), is a type of lungs cancer that occurs in the epithelial tissues of the lungs. NSCLC mostly occurs in people who smoke or have a history of smoking. It also occurs in people who are exposed to polluted air, such as radon, asbestos, and others. The treatment of cancer in patients requires the use of different techniques, such as immunotherapy, targeted therapy, and chemotherapy.

NSCLC can be cured, especially if action is taken before the disease spreads to other organs. Doctor may only need to do surgery if the cancer is contained to a tiny area of the lungs. Additional therapies may be necessary for a more advanced malignancy. Furthermore, rise in tobacco consumption, rising prevalence of non-small lung cancer market, early screening of the cancer, and availability of cancer drugs are expected to boost the market growth. For instance, according to National Centre for Biotechnology Information (NCBI), 85% of lung cancer diseases are non-small cell lung cancer cases.

However, high cost involved in treatment therapies coupled with threat of adverse side-effects associated with cancer drugs therapies is expected to restrain the growth of the market. Conversely, high potential of emerging economies and higher number of potential drugs in pipeline are expected to provide new opportunities for market players in future.

The global NSCLC treatment market is segmented by type, treatment type, distribution channel, and region. Depending on treatment type, the market is divided into chemotherapy, targeted therapy, and immunotherapy. By type, it is categorized into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others (adenosquamous carcinoma, sarcomatoid carcinoma) and by distribution channel, it is segmented into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy.

Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). The major companies profiled in the report include, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly, F. Hoffmann-La Roche Ltd., Johnson & Johnson (Janssen Global Services, LLC), Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, and Teva Pharmaceuticals Industries Ltd.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global non small cell lung cancer market analysis from 2021 to 2031 to identify the prevailing global non small cell lung cancer market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the global non small cell lung cancer market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global non small cell lung cancer market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Squamous Cell Carcinoma
Large Cell Carcinoma
Others
Adenocarcinoma

By Treatment Type

Chemotherapy
Targeted Therapy
Immunotherapy

By Distribution Channel

Hospital Pharmacy
Drug Store and Retail Pharmacy
Online Pharmacy

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Pfizer Inc.
- Astrazeneca
- Eli Lilly and Company
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Celgene Corporation
- Sanofi
- boehringer ingelheim

Product Code: A00544

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

3.1.Market definition and scope
3.2.Key findings
- 3.2.1.Top investment pockets
3.3.Porter's five forces analysis
3.4.Top player positioning
3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TYPE

4.1 Overview
- 4.1.1 Market size and forecast
4.2 Adenocarcinoma
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market share analysis by country
4.3 Squamous Cell Carcinoma
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market share analysis by country
4.4 Large Cell Carcinoma
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market share analysis by country
4.5 Others
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market share analysis by country

CHAPTER 5: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY TREATMENT TYPE

5.1 Overview
- 5.1.1 Market size and forecast
5.2 Chemotherapy
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market share analysis by country
5.3 Targeted Therapy
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market share analysis by country
5.4 Immunotherapy
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market share analysis by country

CHAPTER 6: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY DISTRIBUTION CHANNEL

6.1 Overview
- 6.1.1 Market size and forecast
6.2 Hospital Pharmacy
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market share analysis by country
6.3 Drug Store and Retail Pharmacy
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market share analysis by country
6.4 Online Pharmacy
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market share analysis by country

CHAPTER 7: GLOBAL NON SMALL-CELL LUNG CANCER MARKET, BY REGION

7.1 Overview
- 7.1.1 Market size and forecast
7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Type
- 7.2.3 North America Market size and forecast, by Treatment Type
- 7.2.4 North America Market size and forecast, by Distribution Channel
- 7.2.5 North America Market size and forecast, by country
  - 7.2.5.1 U.S.
  - 7.2.5.1.1 Key market trends, growth factors and opportunities
  - 7.2.5.1.2 Market size and forecast, by Type
  - 7.2.5.1.3 Market size and forecast, by Treatment Type
  - 7.2.5.1.4 Market size and forecast, by Distribution Channel
  - 7.2.5.2 Canada
  - 7.2.5.2.1 Key market trends, growth factors and opportunities
  - 7.2.5.2.2 Market size and forecast, by Type
  - 7.2.5.2.3 Market size and forecast, by Treatment Type
  - 7.2.5.2.4 Market size and forecast, by Distribution Channel
  - 7.2.5.3 Mexico
  - 7.2.5.3.1 Key market trends, growth factors and opportunities
  - 7.2.5.3.2 Market size and forecast, by Type
  - 7.2.5.3.3 Market size and forecast, by Treatment Type
  - 7.2.5.3.4 Market size and forecast, by Distribution Channel
7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Type
- 7.3.3 Europe Market size and forecast, by Treatment Type
- 7.3.4 Europe Market size and forecast, by Distribution Channel
- 7.3.5 Europe Market size and forecast, by country
  - 7.3.5.1 Germany
  - 7.3.5.1.1 Key market trends, growth factors and opportunities
  - 7.3.5.1.2 Market size and forecast, by Type
  - 7.3.5.1.3 Market size and forecast, by Treatment Type
  - 7.3.5.1.4 Market size and forecast, by Distribution Channel
  - 7.3.5.2 France
  - 7.3.5.2.1 Key market trends, growth factors and opportunities
  - 7.3.5.2.2 Market size and forecast, by Type
  - 7.3.5.2.3 Market size and forecast, by Treatment Type
  - 7.3.5.2.4 Market size and forecast, by Distribution Channel
  - 7.3.5.3 UK
  - 7.3.5.3.1 Key market trends, growth factors and opportunities
  - 7.3.5.3.2 Market size and forecast, by Type
  - 7.3.5.3.3 Market size and forecast, by Treatment Type
  - 7.3.5.3.4 Market size and forecast, by Distribution Channel
  - 7.3.5.4 Italy
  - 7.3.5.4.1 Key market trends, growth factors and opportunities
  - 7.3.5.4.2 Market size and forecast, by Type
  - 7.3.5.4.3 Market size and forecast, by Treatment Type
  - 7.3.5.4.4 Market size and forecast, by Distribution Channel
  - 7.3.5.5 Spain
  - 7.3.5.5.1 Key market trends, growth factors and opportunities
  - 7.3.5.5.2 Market size and forecast, by Type
  - 7.3.5.5.3 Market size and forecast, by Treatment Type
  - 7.3.5.5.4 Market size and forecast, by Distribution Channel
  - 7.3.5.6 Rest of Europe
  - 7.3.5.6.1 Key market trends, growth factors and opportunities
  - 7.3.5.6.2 Market size and forecast, by Type
  - 7.3.5.6.3 Market size and forecast, by Treatment Type
  - 7.3.5.6.4 Market size and forecast, by Distribution Channel
7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Type
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
- 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
- 7.4.5 Asia-Pacific Market size and forecast, by country
  - 7.4.5.1 Japan
  - 7.4.5.1.1 Key market trends, growth factors and opportunities
  - 7.4.5.1.2 Market size and forecast, by Type
  - 7.4.5.1.3 Market size and forecast, by Treatment Type
  - 7.4.5.1.4 Market size and forecast, by Distribution Channel
  - 7.4.5.2 China
  - 7.4.5.2.1 Key market trends, growth factors and opportunities
  - 7.4.5.2.2 Market size and forecast, by Type
  - 7.4.5.2.3 Market size and forecast, by Treatment Type
  - 7.4.5.2.4 Market size and forecast, by Distribution Channel
  - 7.4.5.3 Australia
  - 7.4.5.3.1 Key market trends, growth factors and opportunities
  - 7.4.5.3.2 Market size and forecast, by Type
  - 7.4.5.3.3 Market size and forecast, by Treatment Type
  - 7.4.5.3.4 Market size and forecast, by Distribution Channel
  - 7.4.5.4 India
  - 7.4.5.4.1 Key market trends, growth factors and opportunities
  - 7.4.5.4.2 Market size and forecast, by Type
  - 7.4.5.4.3 Market size and forecast, by Treatment Type
  - 7.4.5.4.4 Market size and forecast, by Distribution Channel
  - 7.4.5.5 South Korea
  - 7.4.5.5.1 Key market trends, growth factors and opportunities
  - 7.4.5.5.2 Market size and forecast, by Type
  - 7.4.5.5.3 Market size and forecast, by Treatment Type
  - 7.4.5.5.4 Market size and forecast, by Distribution Channel
  - 7.4.5.6 Rest of Asia-Pacific
  - 7.4.5.6.1 Key market trends, growth factors and opportunities
  - 7.4.5.6.2 Market size and forecast, by Type
  - 7.4.5.6.3 Market size and forecast, by Treatment Type
  - 7.4.5.6.4 Market size and forecast, by Distribution Channel
7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Type
- 7.5.3 LAMEA Market size and forecast, by Treatment Type
- 7.5.4 LAMEA Market size and forecast, by Distribution Channel
- 7.5.5 LAMEA Market size and forecast, by country
  - 7.5.5.1 Brazil
  - 7.5.5.1.1 Key market trends, growth factors and opportunities
  - 7.5.5.1.2 Market size and forecast, by Type
  - 7.5.5.1.3 Market size and forecast, by Treatment Type
  - 7.5.5.1.4 Market size and forecast, by Distribution Channel
  - 7.5.5.2 Saudi Arabia
  - 7.5.5.2.1 Key market trends, growth factors and opportunities
  - 7.5.5.2.2 Market size and forecast, by Type
  - 7.5.5.2.3 Market size and forecast, by Treatment Type
  - 7.5.5.2.4 Market size and forecast, by Distribution Channel
  - 7.5.5.3 South Africa
  - 7.5.5.3.1 Key market trends, growth factors and opportunities
  - 7.5.5.3.2 Market size and forecast, by Type
  - 7.5.5.3.3 Market size and forecast, by Treatment Type
  - 7.5.5.3.4 Market size and forecast, by Distribution Channel
  - 7.5.5.4 Rest of LAMEA
  - 7.5.5.4.1 Key market trends, growth factors and opportunities
  - 7.5.5.4.2 Market size and forecast, by Type
  - 7.5.5.4.3 Market size and forecast, by Treatment Type
  - 7.5.5.4.4 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments

CHAPTER 9: COMPANY PROFILES

9.1 F. Hoffmann-La Roche Ltd
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
9.2 Novartis AG
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
9.3 Pfizer Inc.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
9.4 Astrazeneca
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
9.5 Eli Lilly and Company
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
9.6 Merck & Co., Inc.
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
9.7 Bristol-Myers Squibb Company
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
9.8 Celgene Corporation
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
9.9 Sanofi
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
9.10 boehringer ingelheim
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments